Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593319 | SCV000706890 | uncertain significance | not provided | 2017-03-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001437665 | SCV001640525 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-07-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002384301 | SCV002692630 | likely benign | Cardiovascular phenotype | 2022-02-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004740356 | SCV005359042 | likely benign | JAG1-related disorder | 2024-08-05 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |